28th Jul 2014 15:15
Clinigen Group plc
Holdings in Company
Burton-on-Trent, UK - 28 July 2014 - Clinigen Group plc ('Clinigen' or the 'Company) (AIM: CLIN), the specialty global pharmaceutical company, today announces that it was informed on 25 July 2014 that on 25 July 2014, Thomas Andrew Leaver sold a total of 2,811,850 ordinary shares of 0.1 pence each in the Company. Following this transaction Thomas Andrew Leaver was interested in 1,315,930 ordinary shares in Clinigen; on 28 July 2014, these shares were transferred to Mrs Linda Leaver, Thomas Leaver's mother.
Clinigen was also informed on 25 July 2014, that on 25 July 2014, Samuel Jake Leaver sold a total of 2,811,850 ordinary shares of 0.1 pence each in the Company. Following this transaction Samuel Jake Leaver was interested in 1,315,930 ordinary shares in Clinigen; on 28 July 2014, these shares were transferred to Mrs Linda Leaver, Samuel Leaver's mother.
Mrs Linda Leaver is now interested in a total of 2,631,860 ordinary shares of 1 pence each in the Company, representing approximately 3.2% of Clinigen's issued share capital.
Following these transactions and transfers, neither Thomas Andrew Leaver nor Samuel Jake Leaver are interested in any ordinary shares in Clinigen.
-Ends-
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer | |
Robin Sibson, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) | |
Peel Hunt LLP - Joint Broker | Tel: +44 (0) 20 7418 8900 |
James Steel / Jock Maxwell Macdonald | |
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/ Jen Lewis / Emma Barlow | Email: [email protected] |
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering 'the right drug, to the right patient at the right time', has three operating businesses; Specialty Pharmaceuticals (SP), Clinical Trials Supply (CTS), and Global Access Programs (GAP). SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. GAP specializes in the consultancy, development, management and implementation of programs providing access for patients and their clinicians to drugs not available in their markets.
For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L